Filtered By:
Specialty: Internal Medicine
Source: Evidence-Based Medicine
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 156 results found since Jan 2013.
Parent-reported sleep-disordered breathing symptoms early in life predict childhood behavioural problems at age 4 and 7 years
This study focuses on prospective data collected on children involved in the large-scale, population-based Avon Longitudinal Study of Parents and Children...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Gregory, A. M., Wiggs, L. Tags: EBM Prognosis, Epidemiologic studies, Sleep disorders (neurology), Stroke, Obesity (nutrition), Pregnancy, Sleep disorders, Sleep disorders (respiratory medicine), Screening (epidemiology), Health education, Screening (public health) Source Type: research
Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone
Commentary on: Laine L, Kivitz AJ, Bello AE, et al.. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379–86. Context Non-steroidal anti-inflammatory drugs (NSAID) are widely prescribed worldwide. However, NSAID use frequently accompanies gastrointestinal (GI) injury including complications such as bleeding and perforation. Therefore co-therapy with gastroprotective drugs especially for those at risk has been advocated in current guidelines1 in which proton-pump inhibitors (PPI) and misoprostol ...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Sugano, K. Tags: Clinical trials (epidemiology), Small intestine, Stomach and duodenum, Drugs: cardiovascular system, Stroke, Drugs: musculoskeletal and joint diseases Therapeutics Source Type: research
Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications
Commentary on: Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2012;3:CD004982. Context Superficial thrombophlebitis (ST), an inflammatory-thrombotic disorder in a superficial vein, is relatively common and estimated to occur in 1 per 1000 persons.1 The classic symptoms include pain, oedema, erythema and occasionally a palpable cord in the area of the thrombosed vein. Risk factors for ST include surgery, pregnancy and puerperium, female hormones, malignancy, infection, varicose veins, autoimmune disorders and thrombophilia.2 ST is a risk factor for dee...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: DeSancho, M. T., Pastores, S. M. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Pain (neurology), Stroke, Pregnancy, Venous thromboembolism, Renal medicine, Pulmonary embolism, Drugs: musculoskeletal and joint diseases, Dermatology Therapeutics Source Type: research
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment
Commentary on: EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, et al.. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–97. Context Pulmonary embolism (PE) is a common disease with potentially life-threatening consequences. Current guidelines1 recommend immediate start of anticoagulation with heparin for at least 5 days. Thereafter, heparin may be replaced by vitamin K antagonists (VKAs). The EINSTEIN-PE study tested rivaroxaban for the treatment of acute PE. Rivaroxaban, an oral anti-Xa antagonist, has the major advantage of oral administration wit...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Niessner, A. Tags: Drugs: cardiovascular system, Stroke, Hypertension, Venous thromboembolism, Pulmonary embolism, Drugs: musculoskeletal and joint diseases Therapeutics Source Type: research
Closure of a patent foramen ovale with a device does not offer a greater benefit than medical therapy alone for the prevention of recurrent cerebrovascular events
Commentary on: Furlan AJ, Reisman M, Massaro J, et al.. CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991–9. Context Stroke can rarely be caused by paradoxical emboli passing from the right side of the circulatory system to the left side. Case reports have shown that the most common site of right to left shunt is the patent foramen ovale (PFO), and case control studies have shown a higher prevalence of PFO in patients with cryptogenic stroke as compared to stroke victims with a known cause or non-stroke controls. Therefore, the question ari...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Mattle, H. P., Mono, M.-L. Tags: Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Lipid disorders, Arrhythmias, Health education, Smoking Therapeutics Source Type: research
Dabigatran associated with increased risk of acute coronary events
Commentary on: Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397–402. Context The novel oral anticoagulants, comprised of direct thrombin inhibitors (DTIs) (ie, dabigatran) and the factor Xa inhibitors (ie, rivaroxaban, apixaban and edoxaban), are revolutionising the way patients are anticoagulated. Recent years have witnessed a surge of trials evaluating these drugs in many clinical contexts. However, with such rapid uptake, it becomes critical to carefully evaluate safety data in order ...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Kohli, P., Cannon, C. P. Tags: Electronic pages Source Type: research
